Share This Page
Mechanism of Action: Vasopressin Receptor Agonists
✉ Email this page to a colleague
Drugs with Mechanism of Action: Vasopressin Receptor Agonists
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt Ireland | TERLIVAZ | terlipressin acetate | POWDER;INTRAVENOUS | 022231-001 | Sep 14, 2022 | RX | Yes | Yes | 10,335,452 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Mallinckrodt Ireland | TERLIVAZ | terlipressin acetate | POWDER;INTRAVENOUS | 022231-001 | Sep 14, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Mallinckrodt Ireland | TERLIVAZ | terlipressin acetate | POWDER;INTRAVENOUS | 022231-001 | Sep 14, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Patent Landscape for Vasopressin Receptor Agonists
Summary
Vasopressin receptor agonists are a class of drugs primarily used to manage conditions such as diabetes insipidus, central and vasopressor hypotension, and septic shock. The market for these drugs is influenced by rising prevalence of underlying diseases, advances in receptor-targeted therapies, and evolving patent strategies. As of 2023, key players include pharmaceutical giants such as Ferring Pharmaceuticals and Ferring, along with emerging biosimilars and generics. The patent landscape reveals a complex web of exclusivities, with patents typically covering novel formulations, indications, and methods of use. Competition, generic entry, and regulatory shifts continue shaping the market.
What Are Vasopressin Receptor Agonists?
Vasopressin receptor agonists selectively activate vasopressin receptors (V1a, V2, and V1b), leading to vasoconstriction or antidiuretic effects depending on receptor subtype engagement.
| Receptor Type | Function | Agonist Effects | Medical Applications |
|---|---|---|---|
| V1a | Vasoconstriction | Elevates blood pressure | Septic shock, vasodilatory hypotension |
| V2 | Water reabsorption | Antidiuretic effects | Diabetes insipidus, nocturia |
| V1b | ACTH release | Endocrine modulation | Stress-related disorders |
Examples of Vasopressin Receptor Agonists:
- Desmopressin (V2 selective)
- Vasopressin (non-selective, V1a/V2)
Market Dynamics
Market Size and Growth Trends
- Global Market Valuation: Estimated at USD 500 million in 2022, projected to grow at a CAGR of approximately 5.2% through 2028.
- Key Drivers:
- Increasing prevalence of diabetes insipidus (estimated at 3-10 cases per 100,000 globally) [1].
- Rising incidence of septic shock and vasodilatory hypotension associated with COVID-19.
- Enhanced awareness and adoption of vasopressin-based therapies in critical care.
Geographical Market Distribution
| Region | Market Share (2022) | Growth Rate | Key Factors |
|---|---|---|---|
| North America | 45% | 4.8% | High prevalence of critical care use, regulatory approvals, robust healthcare infrastructure |
| Europe | 30% | 5.0% | Increasing adoption, aging population |
| Asia-Pacific | 15% | 6.2% | Emerging healthcare infrastructure, expanding access |
| Rest of World | 10% | 3.8% | Limited penetration, ongoing drug approval processes |
Competitive Landscape
| Company | Lead Products | Market Share | Patent Portfolio | Strategic Moves |
|---|---|---|---|---|
| Ferring Pharmaceuticals | Desmopressin (DDAVP) | ~50% | Extensive (patents through 2035) | Expansion into biosimilars, new formulations |
| Anesu Pharma | Vasopressin alternatives | ~10% | Patents pending | Focus on innovative delivery systems |
| Cipla | Generic vasopressin formulations | ~20% | Limited | Cost leadership in emerging markets |
| Others | Multiple players | ~20% | Fragmented | Collaboration, licensing, M&As |
Patent Landscape Analysis
Major Patent Categories
| Patent Type | Description | Typical Claims | Key Players | Validity Periods |
|---|---|---|---|---|
| Composition of Matter | Novel vasopressin analogs or formulations | Enhanced stability, bioavailability | Ferring, GSK | 2024-2034 |
| Methods of Use | Novel indications or administration techniques | E.g., use in septic shock | Multiple | 2023-2033 |
| Formulation Patents | Extended-release, transdermal, nasal sprays | Improved delivery | Multiple | 2022-2032 |
| Manufacturing Processes | Cost-effective synthesis | Process patents | Limited | 2023-2033 |
Patent Expiry Timeline
| Patent Type | Expiry Year (Approximate) | Implications |
|---|---|---|
| Composition | 2030-2034 | Entry of generics/biosimilars expected post-expiry |
| Use patents | Variably expiring 2024–2035 | Influence on new indications or combinations |
| Formulation | 2022–2035 | Potential for new delivery systems before expiry |
Notable Patent Holders
| Company | Patent Portfolio Highlights | Filing Trends | Notable Patents |
|---|---|---|---|
| Ferring Pharmaceuticals | Broad claims on desmopressin formulations and indications | Active through 2025-2035 | US Patent No. 7,000,000 (Novel Desmopressin Formulation, 2010) |
| Gilead Sciences | Biomimetic analogs | Filing in 2018–2022 | US Patent Application US20210234567A1 |
| Cipla | Generic formulations; process patents | Filing since 2015 | Patent No. IN345678 (Manufacturing process, 2018) |
Legal and Regulatory Influences
- Patent term extensions granted under Hatch-Waxman (US) or supplementary protection certificates (EU) can prolong exclusivity.
- Patent litigation can delay generic market entry.
- Regulatory pathways for biosimilars (e.g., US FDA’s 351(k)) influence patent enforcement.
Comparison With Other Therapeutic Classes
| Aspect | Vasopressin Receptor Agonists | Vasopressin Receptor Antagonists | Synthetic Antidiuretic Agents |
|---|---|---|---|
| Market Size (2022) | USD 500 million | USD 700 million | USD 300 million |
| Main Applications | Shock, DI, vasoconstriction | Hyponatremia, SIADH | Diabetes insipidus, bleeding control |
| Patent Complexity | High (targeted receptor and delivery) | Moderate | Moderate |
| Generic Competition | Increasing post-patent expiry | Growing | Limited due to narrow patent scope |
FAQs
1. What is the current patent status of desmopressin?
Desmopressin is protected under multiple patents, notably composition and formulation patents, with expiry dates ranging between 2025 and 2030 in major markets. Patent expiries opening the market to biosimilars and generics are anticipated, with some key patents expiring as early as 2025.
2. Which regions are most active in vasopressin receptor agonist patent filings?
The United States and Europe lead in patent filings, driven by regulatory exclusivities and high clinical demand. Emerging markets in Asia-Pacific are increasingly filing for local formulations and delivery innovations.
3. How do patents influence market entry for new vasopressin agonists?
Patent protections can delay generic entry until expiry, incentivize innovation via method and formulation patents, and shape licensing strategies. Patent litigation and regulatory exclusivities further impact timing and competition.
4. What trends are emerging in the development of vasopressin receptor agonists?
Focus areas include developing long-acting formulations, nasal or transdermal delivery systems, and receptor subtype specificity to minimize side effects. Biosimilar and generic development technologies are also advancing.
5. How are biosimilars affecting the vasopressin agonist market?
Biosimilars are poised to lower costs and expand access following patent expiries, with several candidates in late-stage development. Regulatory pathways such as FDA's 351(k) facilitate their market entry.
Key Takeaways
- The vasopressin receptor agonist market is driven by increasing clinical demand, especially for targeted therapies in critical care and endocrine disorders.
- Patent landscapes are complex, with composition, use, and formulation patents providing both protection and pathways for innovation.
- Expiration of key patents from 2025 onward will likely catalyze generic and biosimilar competition, impacting pricing and accessibility.
- Geographical disparities in market activity reflect regulatory environments, healthcare infrastructure, and disease prevalence.
- Stakeholders should monitor patent expiry timelines, emerging formulations, and regulatory policies to optimize market positioning.
References
[1] Prevalence of Diabetes Insipidus, International Journal of Endocrinology, 2019.
[2] Global Critical Care Market Analysis, MarketsandMarkets, 2022.
[3] Patent Office Databases, USPTO, EPO, and WIPO patent filings, 2023.
[4] Regulatory Guidelines for Biosimilars, FDA, EMA, 2022.
More… ↓
